Artelo biosciences to present at the q3 virtual investor summit on august 18th

Solana beach, california--(newsfile corp. - august 11, 2021) - artelo biosciences, inc. (nasdaq: artl), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that management will present at the q3 virtual investor summit, hosted by the investor summit group, being held virtually on august 17-18, 2021.andrew yates, phd, senior vice president and chief scientific officer is scheduled to present as follows. randy...
ARTL Ratings Summary
ARTL Quant Ranking